Direkt zum Inhalt
Merck
  • Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer.

Characterization of KIF11 as a novel prognostic biomarker and therapeutic target for oral cancer.

International journal of oncology (2017-11-09)
Kayo Daigo, Atsushi Takano, Phung Manh Thang, Yoshihiro Yoshitake, Masanori Shinohara, Iwau Tohnai, Yoshinori Murakami, Jiro Maegawa, Yataro Daigo
ZUSAMMENFASSUNG

Oral cancer has a high mortality rate, and its incidence is increasing gradually worldwide. As the effectiveness of standard treatments is still limited, the development of new therapeutic strategies is eagerly awaited. Kinesin family member 11 (KIF11) is a motor protein required for establishing a bipolar spindle in cell division. The role of KIF11 in oral cancer is unclear. Therefore, the present study aimed to assess the role of KIF11 in oral cancer and evaluate its role as a prognostic biomarker and therapeutic target for treating oral cancer. Immunohistochemical analysis demonstrated that KIF11 was expressed in 64 of 99 (64.6%) oral cancer tissues but not in healthy oral epithelia. Strong KIF11 expression was significantly associated with poor prognosis among oral cancer patients (P=0.034), and multivariate analysis confirmed its independent prognostic value. In addition, inhibition of KIF11 expression by transfection of siRNAs into oral cancer cells or treatment of cells with a KIF11 inhibitor significantly suppressed cell proliferation, probably through G2/M arrest and subsequent induction of apoptosis. These results suggest that KIF11 could be a potential prognostic biomarker and therapeutic target for oral cancer.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Anti-KIF11 antibody produced in rabbit, affinity isolated antibody, Prestige Antibodies® Powered by Atlas Antibodies, buffered aqueous glycerol solution